Dexmedetomidine After Cardiac Surgery for Prevention of Delirium

PHASE3CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
ICU Delirium
Interventions
DRUG

Dexmedetomidine

Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.

DRUG

Sodium chloride 0.9%

Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.

Trial Locations (9)

5600

CHU de Nantes, Nantes

22000

CHU de Rennes, Rennes

29609

CHRU de Brest, Brest

38000

CHU de Grenoble, Grenoble

75000

CHU la Pitié Salpétrière, Paris

86000

CHU Poitiers, Poitiers

Unknown

Angers university hospital, Angers

Clermont Ferrand university hospital, Clermont-Ferrand

Hôpital Privé Jacques Cartier, Massy

All Listed Sponsors
collaborator

Direction Générale de l'Offre de Soins

OTHER_GOV

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

University Hospital, Brest

OTHER

NCT03477344 - Dexmedetomidine After Cardiac Surgery for Prevention of Delirium | Biotech Hunter | Biotech Hunter